Nordic Cancer Radiation Therapy Market Outlook (2021–2031)

The Nordic cancer radiation therapy market size is expected to reach US$ 1,833.6 million by 2031 from US$ 924.9 million in 2024. The market is estimated to record a CAGR of 10.3% from 2025 to 2031.

Executive Summary and Nordic Cancer Radiation Therapy Market Analysis:

Advanced healthcare systems, widespread access to technology, and strong governmental support for oncology care define the Nordic cancer radiation therapy market. Rising incidence of prostate, breast, and lung cancers has prompted continued investment in precision radiotherapy modalities, including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and image-guided radiotherapy (IGRT). The region benefits from a dense network of specialized cancer centers, sophisticated imaging infrastructure, and integrated electronic health records, enabling streamlined patient workflows and high treatment accuracy. Regional collaboration among Nordic countries, including Sweden, Norway, Denmark, and Finland, supports shared research, clinical training, and protocol standardization, contributing to consistent adoption of advanced radiation therapy techniques across borders.

Opportunities for growth in the Nordic region are centered around digital oncology solutions, AI-assisted treatment planning, and telemedicine-enabled radiation therapy consultation. These innovations allow smaller hospitals and regional centers to access cutting-edge treatment planning, while large cancer hubs maintain high precision and throughput. Government policies emphasizing preventive care, early cancer detection, and equitable healthcare access support the expansion of radiation therapy services. With continued investments in high-technology equipment and workforce training, the Nordic market is well-positioned to maintain leadership in advanced radiotherapy delivery while expanding capabilities in smaller urban and rural centers.

Nordic Cancer Radiation Therapy Market - Strategic Insights:

Nordic Cancer Radiation Therapy Market Segmentation Analysis:

Key segments that contributed to the derivation of the Nordic cancer radiation therapy market analysis are type, cancer type, and end user.

• By type, the cancer radiation therapy market is segmented into external beam radiation therapy and internal beam radiation therapy. The external beam radiation therapy segment dominated the market in 2024.
• Based on cancer type, the cancer radiation therapy market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, head & neck cancer, cervical cancer, and others. The lung cancer segment dominated the market in 2024.
• In terms of end user, the cancer radiation therapy market is segmented into hospitals, specialty clinics, ambulatory and radiotherapy centers, and academic and research institutes. The hospitals segment dominated the market in 2024.

Nordic Cancer Radiation Therapy Market Drivers and Opportunities:

Upward Trend in Cancer Cases

Cancer prevalence in the Nordic countries—Sweden, Norway, Denmark, Finland, and Iceland—is increasing owing to aging populations, lifestyle factors, and high rates of early detection through well-established screening programs. Breast, prostate, lung, and colorectal cancers are among the most frequently diagnosed, with Sweden and Denmark reporting particularly high incidence rates. Improved awareness and robust healthcare infrastructure are leading to earlier diagnosis, resulting in more patients requiring radiation therapy as part of comprehensive cancer care.

Radiation therapy is a cornerstone of oncology treatment in the Nordic region. External beam radiation therapy is widely used due to its versatility across tumor types, while internal beam (brachytherapy) is applied for prostate, gynecological, and cervical cancers. Public healthcare systems ensure that advanced therapies are accessible to a large portion of the population, while specialized oncology centers continue to expand capacity to meet growing patient demand.

Government programs and healthcare investments are supporting infrastructure upgrades, including the introduction of advanced linear accelerators and modern treatment planning software. These efforts ensure that rising cancer prevalence translates into sustained demand for radiation therapy services. Consequently, the increasing number of cancer cases remains a key driver for the Nordic cancer radiation therapy market.

Rising Focus on Precision and Personalized Medicine

Personalized medicine is gaining prominence in the Nordic countries, driven by patient-centric healthcare policies and advanced clinical research. Radiation therapy is tailored to individual patients using tumor-specific imaging, genomic profiling, and precise treatment planning. This enables clinicians to optimize dose delivery while minimizing exposure to healthy tissue, improving treatment efficacy and quality of life.

External beam radiation therapy is leveraging image-guided and intensity-modulated techniques to deliver patient-specific treatments for complex cancers such as prostate, breast, and head & neck tumors. Internal beam therapy is also being customized for individual patients, particularly in prostate and gynecological cancers, supported by advanced dosimetry and planning systems. Nordic hospitals are leaders in integrating AI and advanced imaging technologies to enhance treatment accuracy.

Collaboration among hospitals, universities, and technology providers is accelerating the adoption of personalized radiation therapy across the region. Patients are increasingly informed and prefer therapies with higher precision and fewer side effects. This growing demand for tailored treatment creates significant opportunities for equipment manufacturers, software developers, and healthcare service providers operating in the Nordic cancer radiation therapy market.

Nordic Cancer Radiation Therapy Market Size and Share Analysis:

The Nordic cancer radiation therapy market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report further examines subsegments categorized within type, cancer type, and end user, offering insights into their contribution to overall market performance.

By type, the external beam radiation therapy subsegment dominated the market in 2024. Due to its widespread availability, precision targeting, noninvasive nature, and effectiveness in treating diverse cancers, it is the preferred choice across global oncology practices.

Based on cancer type, the lung cancer subsegment dominated the market in 2024. Due to its high incidence, strong link with smoking and pollution, late‑stage diagnoses, and reliance on advanced radiation techniques, it is the most treated cancer type globally.

In terms of end user, the hospitals subsegment dominated the market in 2024. Hospitals dominated the market since they provide comprehensive cancer care, advanced radiation infrastructure, skilled oncologists, and integrated treatment pathways, making them the primary setting for delivering radiation therapy services.

Nordic Cancer Radiation Therapy Market Report Highlights:

Nordic Cancer Radiation Therapy Market Report Coverage and Deliverables:

The "Nordic Cancer Radiation Therapy Market Size and Forecast (2021 - 2031)" report provides a detailed analysis of the market covering below areas:

• Nordic Cancer Radiation Therapy market size and forecast at regional, and country levels for all the key market segments covered under the scope
• Nordic Cancer Radiation Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Nordic Cancer Radiation Therapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Nordic Cancer Radiation Therapy market
• Detailed company profiles, including SWOT analysis

Nordic Cancer Radiation Therapy Market Geographic Insights:

The geographical scope of the Nordic Cancer Radiation Therapy market report is divided into Sweden, Norway, Denmark, and Finland. Sweden held the largest share in 2024.

Sweden dominates the Nordic cancer radiation therapy market due to its extensive and modern oncology infrastructure, well-trained clinical workforce, and strong national focus on cancer care. Major centers in Stockholm, Gothenburg, and Uppsala offer comprehensive radiotherapy services, including IMRT, IGRT, SBRT, and brachytherapy, integrated with multidisciplinary treatment programs. Swedish hospitals leverage advanced imaging, precision planning systems, and standardized protocols to deliver high-quality, patient-centered care. Sweden’s leadership is reinforced by continuous investment in research, digital health platforms, and training initiatives that ensure the workforce remains proficient in emerging radiotherapy techniques. Its cancer centers frequently collaborate with international institutions, facilitating the adoption of best practices and clinical innovations. As a regional hub, Sweden attracts expertise and drives standards across the Nordic countries, consolidating its position as the primary force shaping radiation therapy development and innovation in the region.

Nordic Cancer Radiation Therapy Market Research Report Guidance:

• The report includes qualitative and quantitative data in the Nordic cancer radiation therapy market across type, cancer type, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Nordic Cancer Radiation Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Nordic Cancer Radiation Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Nordic Cancer Radiation Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 10 cover Nordic Cancer Radiation Therapy market segments by type, cancer type, end user, and geography across Sweden, Norway, Denmark, and Finland. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the Nordic Cancer Radiation Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

Nordic Cancer Radiation Therapy Market News and Key Development:

The Nordic Cancer Radiation Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Nordic cancer radiation therapy market are:

• In June 2025, RaySearch Laboratories AB, a Swedish developer of radiation therapy treatment planning software, announced that its RayStation platform was used in the first European clinical treatments with accelerator‑based boron neutron capture therapy (BNCT) at Helsinki University Hospital in Finland, marking a significant clinical milestone for advanced radiotherapy planning in the region.
• In June 2023, Nordic Nanovector ASA announced that it entered into a share exchange agreement to acquire Thor Medical AS, a Norwegian alpha‑emitter production company, to combine capabilities in radionuclide‑based cancer therapies (including radiotherapeutic development), subject to shareholder approval and aiming to strengthen its position in cancer treatment innovation.

Key Sources Referred:

• The World Bank
• World Health Organization (WHO)
• Center for Disease Control and Prevention (CDC)
• Union for International Cancer Control (UICC)
• International Agency for Research on Cancer (IARC)
• American Society for Radiation Oncology (ASTRO)
• European Society for Radiotherapy & Oncology (ESTRO)
• Asia-Oceania Federation of Organizations for Radiological Technology (AOFRT)
• Company Websites
• Company Annual Reports
• Company Investor Presentations